Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.1953
Abstract: Fatigue is distressing and affects quality of life (QoL) among patients with myelodysplastic syndrome (MDS), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH). Limited data exist on the impact of fatigue, QoL, and related symptoms… read more here.
Keywords: aplastic anemia; patients myelodysplastic; fatigue; anemia paroxysmal ... See more keywords
Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution
Sign Up to like & getrecommendations! Published in 2020 at "Genes"
DOI: 10.1002/gcc.22841
Abstract: The karyotype of bone‐marrow cells at the time of diagnosis is one of the most important prognostic factors in patients with myelodysplastic syndromes (MDS). In some cases, the acquisition of additional genetic aberrations (clonal evolution… read more here.
Keywords: clonal evolution; myelodysplastic syndromes; mds specific; patients myelodysplastic ... See more keywords
Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Sign Up to like & getrecommendations! Published in 2020 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2019.10.006
Abstract: Iron overload (IOL) in patients with myelodysplastic syndromes (MDS) is mainly attributable to chronic transfusion therapy. The importance of iron chelation therapy (ICT) in MDS has been a matter of debate. The Telesto study, the… read more here.
Keywords: myelodysplastic syndromes; trial; patients myelodysplastic; iron chelation ... See more keywords
The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.12.002
Abstract: BACKGROUND Severe thrombocytopenia affects 10% of patients with myelodysplastic syndrome (MDS) and is associated with poor outcomes. The role for prophylactic platelet transfusions in the outpatient setting is unknown. OBJECTIVE/METHODS To audit treatments, bleeding rates,… read more here.
Keywords: thrombocytopenia; patients myelodysplastic; severe thrombocytopenia; myelodysplastic syndrome ... See more keywords
Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.106175
Abstract: Deletion of the long arm of chromosome 20 (del(20q)) is observed in 5-10% of patients with myelodysplastic syndromes (MDS). We examined the expression of 28 genes within the common deleted region (CDR) of del(20q), which… read more here.
Keywords: myelodysplastic syndromes; patients myelodysplastic; within common; common deleted ... See more keywords
Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2021 at "Hematology"
DOI: 10.1080/16078454.2021.1889161
Abstract: OBJECTIVES To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML). METHODS A total of 2,400 adults… read more here.
Keywords: myelodysplastic syndromes; patients myelodysplastic; persistent patients; non persistent ... See more keywords
Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000021900
Abstract: Abstract Background: Gene mutations with important prognostic roles have been identified in patients with myelodysplastic syndrome (MDS). Overall, it is not yet fully clear whether enhancer of zeste homolog 2 (EZH2) is affected and contributes… read more here.
Keywords: patients myelodysplastic; zeste homolog; myelodysplastic syndrome; effect ... See more keywords
Hypomegakaryocytic thrombocytopenia and increased number of PNH‐phenotype cells – an emerging subgroup of myelodysplastic syndrome showing frequent response to immunosuppression – RESPONSE to Rafferty & Leach
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14755
Abstract: Fozza, C., Contini, S., Galleu, A., Simula, M.P., Virdis, P., Bonfigli, S. & Longinotti, M. (2009) Patients with Myelodysplastic Syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in… read more here.
Keywords: myelodysplastic syndromes; response; patients myelodysplastic; haematology ... See more keywords
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13641
Abstract: To assess whether socioeconomic indices such as income and educational level can explain part of the variation in survival among patients with myelodysplastic syndromes, and further to assess whether these factors influence care and treatment… read more here.
Keywords: myelodysplastic syndromes; impact treatments; patients myelodysplastic; education impact ... See more keywords
Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13820
Abstract: Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case… read more here.
Keywords: management infection; mindset study; myelodysplastic syndromes; patients myelodysplastic ... See more keywords
Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13865
Abstract: In patients with myelodysplastic syndromes (MDS) with >20 transfusions and ferritin levels >1000 μg/L, international guidelines recommend iron chelation therapy (ICT). The study's objective was to determine guideline adherence and the intensity of ferritin monitoring in… read more here.
Keywords: ferritin; iron chelation; myelodysplastic syndromes; guideline adherence ... See more keywords